You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
6 May 2024
Immunic to Participate in Investor and Scientific Conferences in May
1 May 2024
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update
30 April 2024
Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in RRMS in the Peer Reviewed Journal, Neurology® Neuroimmunology & Neuroinflammation
4 April 2024
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
20 March 2024
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
7 March 2024
Immunic to Participate in Investor and Scientific Conferences in March